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Thyroid cancer is among the most common cancers and is the most frequent type of 
endocrine malignancy (Kirschner et al., 2016). It has also been increasing in prevalence over the 
past decade (Davies et al., 2015). Increased risk of thyroid cancer has been associated with 
Cowden syndrome (CS), which is an inherited endocrine tumor disorder. CS is characterized by 
the presence of small tumor-like growths, known as hamartomas, and has been found to provide 
an increased risk of the development of other tumors (Nagy et al., 2004). Germline mutations in 
the phosphatase and tensin homolog (PTEN) tumor suppressor gene have been shown to cause 
CS and are identified in 85% of CS-associated and 10% of sporadic thyroid cancers (Yeager et 
al., 2007). In addition, germline variations in the succinate dehydrogenase complex (SDH) genes, 
which were first identified as tumor suppressor genes in patients with pheochromocytoma and 
paraganglioma, have been recently discovered in CS patients with thyroid cancer (Ni et al., 
2008). Physiologically, SDH functions in the citric acid cycle where it catalyzes the conversion 
of succinate to fumarate within the mitochondrial intermembrane space, and thus plays a crucial 
role in metabolic processes (Cantor et al., 2012). Activation and induction of carcinogenic 
cellular environment can occur through changes in metabolic pathways involving a shift from 
aerobic respiration to anaerobic glycolysis, which is known as the Warburg effect (Cantor et al., 
2012). These changes could potentially be caused by alterations in genes coding for 
mitochondrial enzymes, such as SDH, consequently impacting normal cellular metabolism and 
leading to cancerous effects (Cantor et al., 2012). 
SDH is composed of four protein subunits (A, B, C, and D), of which succinate 
dehydrogenase subunit D (SDHD) gene possesses a relatively high frequency of germline 
variations found within the patient population, thus making it a gene of interest within this study 
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(Bayley et al., 2005). Studies have shown that CS patients with variations in the SDHD gene 
either alone or in combination with PTEN mutations display an increased risk for thyroid as well 
as breast cancers in comparison to CS patients with only PTEN mutations (Ni et al., 2012). 
Hence, changes in SDHD functionality due to genetic variations may confer a unique thyroid-
specific effect leading to the greater tumor progression observed within those patients with 
alterations in the SDHD gene.  
Previous studies from the Kirschner Lab examining tumor development within the thyroid glands 
compared thyroid-specific Sdhd deletion and thyroid-specific Sdhd/Pten deletion experimental 
models to Sdhd-wildtype and thyroid-specific Pten deletion control models, respectively. Based 
on ultrasound imaging of thyroid glands and histopathological staining of follicular regions, 
Sdhd-null models were found to display larger thyroid volumes, and along with Sdhd/Pten-null 
models exhibited decreased follicle area, and increased cell density and proliferation; however, 
Sdhd/Pten-null models displayed actual tumors more often than Sdhd-null models 
Studies examining germline variations in SDHD have identified the His50Arg (H50R) 
variation as being associated more frequently with sporadic thyroid tumor cases in patients both 
with and without the presence of a PTEN mutation (Bardellae et al., 2011). The H50R genetic 
alteration is caused by a missense mutation involving a single nucleotide change that results in 
the mRNA codon translating for the amino acid arginine instead of the amino acid histidine. 
While frequent mutations can be identified within human cancer patients, the manner with which 
these mutations can lead to the development of such tumor disorders may not be fully 
understood. Specifically, it is unknown whether missense mutations in SDHD produce 
tumorigenic effects within the thyroid glands, as well as how these tumors might occur. 
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Therefore, it is essential to model this tumor progression in vivo to better understand how such 
mutations in the human patient population lead to thyroid and other cancers.  
The hypothesis for this research study is that Sdhd H50R mutant allele will promote 
tumorigenesis and lead to the development of tumors within the murine thyroid. Patients with 
this missense mutation have been shown to have greater incidence of thyroid cancers and display 
downstream effects on targets commonly found in tumorigenic pathways. Since SDHD has been 
identified as a tumor suppressor in other endocrine tumor disorders, it is expected that the 
tumorigenesis resulting from H50R mutation will be due to the loss of Sdhd function caused by 
the genetic alteration, acting as an impetus for the thyroid tumor development.   
 
Materials and Methods 
As the research project focuses on examining the effects of the SdhdH50R mutation on 
thyroid tumorigenesis, the experimental design will focus on characterizing these effects through 
methods that assess gross anatomical changes, histological alterations on a cellular level, and the 
potential effect on sub-cellular processes including metabolism. This will be able to provide a 
holistic picture of the impact that the SdhdH50R mutation has regarding multiple stages of tumor 
progression in the thyroid glands.  
Animal Strains, Husbandry and Maintenance 
The use of animals complied with federal and The Ohio State University Laboratory 
Animal Resources regulations (IACUC Protocol # 2009A0084-R3). Mouse models with thyroid-
specific Sdhd deletion and/or Sdhd H50R mutation were generated, using CRISPR-Cas9 genome 
editing to generate a heterozygous Sdhd H50R mutant founder. Several generations of breeding 
between the founder and a mouse with thyroid-specific Sdhd deletion produced Sdhd H50R 
6 
 
mutation (SdhdH50R/Wt), homozygous Sdhd mutation (SdhdH50R/H50R), and heterozygous Sdhd 
H50R mutation with thyroid-specific deletion of the non-mutant Sdhd allele (Tpo-SdhdH50R/-), 
also referred to as hemizygous Sdhd H50R. Control mouse models (generated within the same 
cohorts as the experimental models) included thyroid-specific Sdhd deletion (Tpo-Sdhd-/-) as a 
positive control and wildtype Sdhd (SdhdWt/Wt) as a negative control. The experiments were 
performed using littermate mice from a mixed C57BL/6 and FVB genetic background. 
Genotyping and Sanger Sequencing 
Polymerase chain reaction (PCR), conducted using Go-Taq protocol with primers 
specific for Sdhd-lox and TPO-cre, and Sanger Sequencing, performed through the Genomics 
Shared Resource at The Ohio State University, were utilized to verify the types of Sdhd alleles 
and if the H50R mutation was present in each model.  
Survival Analysis 
Due to spontaneous early demises occurring among mutant models, date of death of 
individual mice were noted up to 12 months. This data was plotted on a Kaplan-Meier curve 
using PRISM software to evaluate the trends in SdhdH50R mutant models’ survival. 
Body Mass Measurements 
 Body mass of individual mice was measured after 12 months using a portable weighing 
scale with accuracy to the nearest tenth of a gram. 
Ultrasonography 
Mice were imaged with a VisualSonics Vevo 2100 (VisualSonics, Toronto, CA, USA) 
after 12 months of age. MS550D transducer (22–55 MHz) was used with 3D-mode imaging to 
determine the size of the thyroid. The volume of both thyroid lobes was calculated using 




The hematoxylin and eosin (H&E)-stained sections of thyroid and adrenal glands were 
processed and produced by the Comparative Pathology Services at The Ohio State University. 
The samples of thyroid and adrenal glands were imaged at 20× magnification. 
Mouse Embryonic Fibroblast (MEF) Isolation and Cell Culture 
Mouse embryos were isolated from pregnant females (through SdhdH50R/Wt crossings) and 
after liver/heart tissue was removed, each embryo was individually chopped using a sterilized 
blade and digested in 0.25% trypsin-EDTA for a total of 1 hour. Cells were combined with 40 
mL of DMEM growth media, centrifuged at 350g for 10 minutes, and the pellet was resuspended 
in 10 mL of DMEM and plated onto 10 mm diameter plates. Cell lines were cultured for two 
passages and then frozen at -80°C. 
Cell Proliferation/Growth 
Twenty thousand cells were plated in 12-well plates for a growth curve by crystal violet 
assay. At each time point, triplicate wells were stained with 0.05% crystal violet, 0.1% formalin 
for 20 min and extracted with 10% acetic acid. Absorbance was measured at 590 nm. 
Mitochondrial Stress Assay 
Seahorse XF Cell Mito Stress Test was used to measure the oxygen consumption rate (OCR) via 
the Seahorse XF Cell Mito Stress Test Kit and respective Report Generator. MEF cells 
(SdhdH50R/Wt, SdhdH50R/H50R, SdhdWt/Wt) were plated at a density of 20,000 cells per well (XF24 
cell culture microplate; Seahorse Biosciences, North Billerica, MA, USA). The cells were 
allowed to grow for 24-hours, following which the cells were washed with XF Assay media 
(with 20 mM glucose, 1 mM sodium pyruvate, no sodium bicarbonate at pH 7.4). The cells were 
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incubated for 1 hour at 37°C in a non-CO2 incubator. The assay was normalized to cell count and 
analyzed using the XFe24 analyzer and corresponding Wave software. 
 
Results 
Figure 1: Impact on survival and weight gain for SdhdH50R mutants. (A) Survival analysis of 
global H50R homozygous (n=46), heterozygous (n=76), and wildtype mice (n=25). (B) Lower 
SdhdH50R/H50R mass. 
 
Sdhdh50r Mutants Demonstrate Changes in Overall Lifespan and Size 
Being the first ever global SdhdH50R mutant mouse models, an important query of this 
project involved examining the potential for embryonic lethality for SdhdH50R mutants, which had 
been established as a consequence of global ablation of Sdhd in previous mouse models. 
However, all mice possessing an H50R mutation in this study were found to be embryonically 
viable and also demonstrated a capacity to reproduce. Yet, it was observed that mice possessing 
one or two copies of the SdhdH50R allele exhibited lower rates of survival in comparison to the 
wildtype controls, with the greatest decrease in survival observed after 200 days for SdhdH50R/Wt 
and 300 days for SdhdH50R/H50R (Figure 1A). Due to the global SdhdH50R mutation, we were 
interested in identifying any gross physiological changes in mutant models. When comparing 
body weight between mutants and wildtype models for both male and female mice, it can be 
9 
 
noted that SdhdH50R/H50R males and females possess significantly lower body weights than the 
respective SdhdH50R heterozygotes and wildtype models (Figure 1B).  
Figure 2: Thyroid volumes are not significantly affected. (A) Volumes of thyroid glands from 
experimental and control models at six months of age. (B) Representative 3-D structures and 
volumes of thyroid glands from experimental and control groups at 12 months of age. 
 
SdhdH50R Models Lack Increases in Thyroid Volume 
Changes in thyroid volumes can be indicative of initiation of tumorigenesis and also act 
as a precursor for tumor progression. When comparing thyroid volumes at 6 months of age, it 
was observed that there was no significant difference between the mutant SdhdH50R models and 
the controls (Figure 2A). However, at 12 months of age, mouse thyroids of models with 
homozygous (n=10) and heterozygous SdhdH50R (n=10) mutations were more similar in volume 
to Sdhd-wildtypes (n=5) and in normal physiological range, as compared to Sdhd-KO (n=6) 
controls which had much larger thyroid volumes (Figure 2B). 
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Figure 3: SdhdH50R mutation led to alterations in thyroid follicles. Representative histological 
images at 20X magnification for (A) SdhdH50R homozygous thyroid tissue (n=2), (B) SdhdH50R 
heterozygous thyroid tissue (n=3), and (C) Sdhd-wildtype thyroid tissue (n=2). 
Figure 4: Global effects of SdhdH50R mutation on adrenal gland medulla and cortex regions. 
Representative histological images at 20X magnification for (A) SdhdH50R homozygous adrenal 
tissue (n=2), (B) SdhdH50R heterozygous adrenal tissue (n=3), and (C) Sdhd-wildtype adrenal 
tissue (n=3). 
 
Follicular Dysplasia Present in SdhdH50R Mutant Tissue 
Due to alterations in cellular structure within thyroid tissue being a key component of 
tumor progression, we examined sections thyroid tissues which revealed that both heterozygous 
and homozygous mutant models possessed significant changes indicating cellular proliferation 
and dysplasia surrounding the thyroid follicles in comparison to wildtype models (Figure 3A-
3C). Additionally, to the potential effects in other endocrine tissues due to the global nature of 
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the SdhdH50R mutation, adrenal gland tissues were also studied and revealed changes with cellular 
proliferation within the regions of cells including the adrenal medulla (Figure 4A-4C). 
Figure 5: SdhdH50R mutant cells demonstrate variation in cellular energy production 
despite normal growth over time. (A) Cellular growth for SdhdH50R mutant and wildtype cells 
(Replicates of 10 samples). (B) Mitochondrial function graph for cell lines over stress assay 
progression. (C) Glycolytic rate for cell lines during stress assay. (D) Spare capacity graph for 
mutant and wildtype cells. (E) Non-mitochondrial oxygen consumption for mutant and wildtype 
cells. (F) ATP-production for mutant and wildtype cells. 
 
H50R Mutation in Sdhd Gene Results in Deregulation on Cellular Energetics in MEF Cell Lines 
Since the Sdhd gene functions within the SDH protein complex in the mitochondria, it 
was critical to investigate changes caused by the missense mutation that could have affected 
cellular growth and metabolism and promoted tumor progression. Cellular proliferation assays 
revealed that there was no significant difference in growth among all the timepoints between cell 
lines with at least one copy of the H50R mutation and wildtype cells (Figure 5A). However, 
assessments of mitochondrial function indicated significant differences in mitochondrial function 
based on trends of oxygen consumption rate (OCR) (Figure 5B). In particular, SdhdH50R mutant 
cell lines exhibiting statistically significant increases in spare capacity and ATP production 
values, as well as significant decreases in non-mitochondrial oxygen consumption in comparison 
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to wildtype cell lines (Figure 5D-5F). Additionally, mutant cell lines also exhibited greater trends 
in extra-cellular acidification rate (ECAR) values compared to wildtype cells (Figure 5C). 
 
Discussion 
While ablation of the Sdhd gene in mice has commonly led to certain characteristics 
indicative of tumorigenic pathways and altered physiological state, this study showed unique 
effects of the SdhdH50R missense mutation within the murine models. The embryonic viability of 
mice with global homozygous SdhdH50R alleles demonstrated that the mutation did not have the 
same developmental defects that occurred among global Sdhd-knockouts. However, despite 
embryonic viability, SdhdH50R mutant mice displayed lower rates of survival within one year, 
with discernable trends of lifespan between homozygous, heterozygous, and wildtype models. 
Given the statistically significant lower body masses among SdhdH50R homozygotes, this 
indicates a potential global effect that could involve mice wasting away and thus having lower 
survival rates and body weights. However, since initial dissection studies have revealed that the 
variation in weight may be largely due to differences in the amount of adipose tissue present in 
the mice, it could be possible that the mutation may be affecting the overall metabolism in mice 
and leading to less accumulation of fats and subsequently reducing overall lifespan. 
When specifically examining the effects of the missense mutation on the thyroid glands, 
it was noticed that thyroid volumes for mutant models were smaller compared to KO-models and 
more similar to wildtype controls after one year. This, along with the lack of significant growth 
at early timepoints could be indicative that the SdhdH50R mutation may lack the robust phenotype 
associated with large increases in tumor volume observed with thyroid-specific deletions, and 
that the effects of the mutation within thyroid gland may be subtler.  
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Upon looking at the histology of the thyroid gland, it could be identified that severe 
alterations had been occurring within the follicular regions of the thyroids. The pathology of the 
thyroid glands for all mouse models revealed that were no tumors present within the thyroid. 
However, closer analysis of the thyroid tissue revealed dysplasia of follicle areas, with greater 
cellular proliferation and an observable decrease in the follicular areas in SdhdH50R homozygous 
and heterozygous models compared to Sdhd-wildtype. These cellular changes indicate putative 
tumor initiation pathways within the thyroid tissue that may be of consequence within the 
SdhdH50R models despite the normal size of the thyroid glands, indicating a potential 
restructuring of the thyroid gland that is consistent with initial tumor formation. Increased 
cellular proliferation also observed in the medulla and cortex boundaries of adrenal glands 
signified the global physiological impact of the H50R mutation, including affecting other 
endocrine system organs as well as potential cellular neoplasia within the adrenal glands. These 
effects observed within the heterozygous mutant mouse may suggest the initiation of tumor 
development caused by the missense mutation and display potential progression to cancer at 
further stages. 
The cellular data shown in the proliferation assay revealed that despite changes occurring 
at the tissue level, the overall growth of cells with the SdhdH50R mutation did not differ 
significantly for cells without the mutation. Upon a closer examination of the mitochondrial 
function of the cell lines, it was determined that cells possessing at least one copy of the mutant 
allele demonstrated greater mitochondrial function. This was shown by the elevations in spare 
capacity and ATP-production, which indicated that cells with the mutation were able to respond 
to greater metabolic demands and that the overall energetic pathways within the mitochondria 
had been altered. Furthermore, the lower levels of non-mitochondrial oxygen consumption 
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revealed the relative high functionality of the mitochondria as well as the fact that oxidation of 
free radicals and inflammatory biomarkers were reduced. This postulates that there is an increase 
in mitochondrial activity. Additionally, glycolytic rates, which were indicated by ECAR values, 
were greater in mutation cell lines compared to wildtype cells. These two findings reveal that 
while the mutation does not seem to cause the types of metabolic changes associated with the 
Warburg effect, which include reduced mitochondrial oxidative phosphorylation and increased 
glycolysis, it can be seen that the mutation does result in a deregulation of cellular energetic 
pathways and may be the first step in potentially driving metabolism that is more favorable to a 
tumor environment. 
Overall, it was observed that the SdhdH50R mutation resulted in the unique effects, with 
significant global effects across multiple tissues and yet lacked certain characteristics common to 
tumor models, given the reduced thyroid volumes and variation from energetic pathways based 
on the Warburg effect. However, both murine and cellular models with the H50R mutation did 
demonstrate several aspects of dysregulation and alterations that could be responsible for 
potential tumor progression. Contrary to the initial hypothesis, SdhdH50R homozygous and 
heterozygous models demonstrated similar effects, as seen with reduced viability, similar thyroid 
volumes, tissue dysplasia, and common deregulation of cellular energetics. This may imply that 
the SdhdH50R mutation may not function completely within a loss-of-function genetic mechanism 
and could possible have either a gain-of-function effect, given the unique cell metabolism, or 
even a dominant-negative impact, resulting in similar phenotypes between the SdhdH50R 
homozygous and heterozygous models. To fully elucidate the nature of this mutation, it would be 
critical to conduct protein analyses to examine downstream molecular targets within the Sdhd 
and Pten signaling pathways, which can be critical for tumor pathways. Additionally, looking 
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into the certain metabolic byproducts of the Krebs cycle and oxidative phosphorylation chain 
may also provide insight regarding changes in functionality due to the mutation. Finally, since 
Pten can often alter the effects of the Sdhd within a tumor model, it would be essential to create 
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